ClinicalTrials.gg
TerminatedNCT01665430Updated Feb 8, 2018Results posted

A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of Tocilizumab in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 4 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-08.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated by sponsor due to market authorization of tocilizumab for the study population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
85th of 110
38 · median 97
Started
2012
with 10 others
Phase 3
65 of 110
none open now
Registered
65th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 85th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 65th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This multicenter, open-label, single arm long-term extension of study WA19926 will evaluate the safety and efficacy of tocilizumab (RoActemra/Actemra) in participants with early, moderate to severe rheumatoid arthritis who have completed the WA19926 core study. Eligible participants will receive tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who complete WA19926 core study (visit at Week 104 and two follow-up telephone visits) and who may benefit from study drug treatment according to the Investigator's assessment
  • No current or recent adverse event or laboratory finding preventing the use of the study drug dose of tocilizumab 8 mg/kg at baseline visit
  • Receiving treatment on an outpatient basis
  • Females of must agree to use at least one adequate method of as defined by protocol during the treatment period

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Participants who have prematurely withdrawn from the WA19926 study for any reason
  • Treatment with any agent or cell depleting therapies since last administration of study drug in the WA19926 core study
  • Treatment with an anti-tumor necrosis factor (TNF) or anti-interleukin (IL)1 agent, or a T-cell co-stimulation modulator since the last administration of the study drug in the WA19926 core study
  • Immunization with a live/attenuated vaccine since the last administration of study drug in the WA19926 core study
  • Diagnosis since visit at Week 104 of the core WA19926 study of rheumatic disease other than rheumatoid arthritis
  • Diagnosis since visit at Week 104 of the core WA19926 study of inflammatory joint disease other than rheumatoid arthritis
  • Evidence of serious uncontrolled concomitant disease or disorder
  • Known active or history of recurrent infection
  • Current liver disease as determined by Investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab 8 milligrams per kilogram (mg/kg) intravenous infusion every 4 weeks up to 104 weeks.

    Drug: Tocilizumab

Interventions

  • Tocilizumab will be administered at 8 mg/kg intravenous infusion every 4 weeks, up to 104 weeks.

    Also known as: RoActemra/Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs), AEs of Special Interest and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs include serious as well as non-serious AEs. AEs of special interest included: Infections including all opportunistic infections and non-serious infections as defined by those treated with IV anti-infectives; Myocardial infarction/acute coronary syndrome; Gastrointestinal perforations and related events; Malignancies; Anaphylaxis/Hypersensitivity reactions; Demyelinating disorders; Stroke; Bleeding events; and Hepatic events.

    Time frame: Baseline up to 112 weeks

Secondary outcomes

  1. Change From Baseline in Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Score

    DAS28-ESR was calculated from swollen joint count and tender joint count using 28 joints count, erythrocyte sedimentation rate (ESR, in millimeters per hour \[mm/hour\]) and patient global assessment (PtGA) of disease activity (participant rated arthritis activity assessment on a 0 to 100 millimeter \[mm\] visual analog scale \[VAS\]; higher scores indicating greater affectation due to disease activity). Total DAS28-ESR transformed score range: 0 to approximately 10, higher score=more disease activity. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to Week 104)

  2. Change From Baseline in Total Tender Joint Counts (28 Joints)

    The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 28 joints and joints were classified as tender/not tender giving a total possible tender joint count of 0 to 28. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to Week 104)

  3. Change From Baseline in Total Swollen Joint Counts (28 Joints)

    The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1, for 28 joints and were classified as swollen/not swollen giving a total possible swollen joint count of 0 to 28. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to Week 104)

  4. Percentage of Participants With Drug-Free Remission

    Drug-free remission was defined as having clinical remission (defined as DAS28-ESR score \<2.6) for 2 consecutive assessment visits followed by discontinuation of tocilizumab at the second assessment visit. DAS28-ESR was calculated from swollen joint count and tender joint count using 28 joints count, ESR, (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment on a 0 to 100 mm VAS; higher scores indicating greater affectation due to disease activity). Total DAS28-ESR transformed score range: 0 to approximately 10, higher score=more disease activity.

    Time frame: Baseline up to Week 104 (assessed at Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit [Week 104], at early withdrawal [up to 104 weeks])

  5. Percentage of Participants With Clinical Remission

    Clinical remission was defined as having DAS28-ESR score \<2.6 at any point during the study. DAS28-ESR was calculated from swollen joint count and tender joint count using 28 joints count, ESR, (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment on a 0 to 100 mm VAS; higher scores indicating greater affectation due to disease activity). Total DAS28-ESR transformed score range: 0 to approximately 10, higher score=more disease activity.

    Time frame: Baseline up to Week 104 (assessed at Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit [Week 104], at early withdrawal [up to 104 weeks])

  6. Time to Rheumatoid Arthritis (RA) Flare in Participants Who Had Entered Drug-Free Remission

    Time to RA flare was defined as the period of drug-free remission (having DAS28-ESR score \<2.6 for 2 consecutive assessment visits followed by discontinuation of tocilizumab at the second assessment visit) until documented RA flare. RA flare was defined as any worsening of the participant's disease activity that, in the opinion of the Investigator, required treatment intensification beyond supportive therapy which could include restarting the study drug.

    Time frame: Baseline up to Week 104 (assessed at Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit [Week 104], at early withdrawal [up to 104 weeks])

  7. Change From Baseline in Physician's Global Assessment (PGA) of Disease Activity Using Visual Analog Scale (VAS)

    The PGA of disease activity was assessed using a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equaled 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equaled 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicated improvement. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)

  8. Change From Baseline in PtGA of Disease Activity Using VAS

    The PtGA of disease activity was assessed using a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equaled 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equaled 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicated improvement. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)

  9. Change From Baseline in Participant Assessment of Pain Using VAS

    Severity of pain was evaluated by a VAS. Participants marked on a 100 mm horizontal VAS the severity of pain that they had experienced because of their RA, ranging from 0 mm (no pain) to 100 mm (unbearable pain). Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)

  10. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

    The HAQ-DI was a participant self-reported questionnaire for assessing the extent of a participant's functional ability. It consisted of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question had 4 response options, ranging from 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The HAQ-DI scale was an average of all the scores from all questions and ranged from 0 to 3, where higher scores represented higher disease activity. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from study for reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

    Time frame: Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)

07

Results

Posted Feb 8, 2018
Limitations and caveats
The study was terminated due to sponsor decision which was due to market authorization of tocilizumab for the treatment of severe, active and progressive RA in adults not previously treated with methotrexate.

Participant flow

The study included participants with early, moderate to severe rheumatoid arthritis (RA) who had completed WA19926 (NCT01007435) core study and who may have benefited from tocilizumab treatment based on the Investigator's judgment.

Participant flow — Overall Study
MilestoneTocilizumab
Started38
Completed29
Not completed9
Withdrew: Adverse event1
Withdrew: Withdrawal by subject6
Withdrew: Other unspecified2

Outcome measures

PrimaryPercentage of Participants With Adverse Events (AEs), AEs of Special Interest and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs include serious as well as non-serious AEs. AEs of special interest included: Infections including all opportunistic infections and non-serious infections as defined by those treated with IV anti-infectives; Myocardial infarction/acute coronary syndrome; Gastrointestinal perforations and related events; Malignancies; Anaphylaxis/Hypersensitivity reactions; Demyelinating disorders; Stroke; Bleeding events; and Hepatic events.

Time frame:
Baseline up to 112 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs), AEs of Special Interest and Serious Adverse Events (SAEs)
percentage of participantsTocilizumab
AE65.8
AEs of Special Interest34.2
SAE7.9
SecondaryChange From Baseline in Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Score

DAS28-ESR was calculated from swollen joint count and tender joint count using 28 joints count, erythrocyte sedimentation rate (ESR, in millimeters per hour \[mm/hour\]) and patient global assessment (PtGA) of disease activity (participant rated arthritis activity assessment on a 0 to 100 millimeter \[mm\] visual analog scale \[VAS\]; higher scores indicating greater affectation due to disease activity). Total DAS28-ESR transformed score range: 0 to approximately 10, higher score=more disease activity. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to Week 104)
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR) Score
units on a scaleTocilizumab
Baseline4.365 ± 1.5502
Week 12-1.832 ± 1.1985
Week 24-1.496 ± 1.2683
Week 36-1.904 ± 1.1682
Week 48-1.970 ± 1.4503
Week 56-1.979 ± 1.4368
Week 68-2.069 ± 1.2486
Week 80-1.831 ± 1.2592
Week 92-1.792 ± 1.0792
End of Study-2.187 ± 1.1785
Early Withdrawal-1.624 ± 1.8930
SecondaryChange From Baseline in Total Tender Joint Counts (28 Joints)

The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1, for 28 joints and joints were classified as tender/not tender giving a total possible tender joint count of 0 to 28. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to Week 104)
Reported as:
Mean · tender joints
Change From Baseline in Total Tender Joint Counts (28 Joints)
tender jointsTocilizumab
Baseline12.6 ± 16.54
Week 12-7.7 ± 12.63
Week 24-5.0 ± 10.95
Week 36-6.1 ± 13.13
Week 48-6.1 ± 11.17
Week 56-7.6 ± 11.89
Week 68-7.2 ± 9.63
Week 80-10.0 ± 13.74
Week 92-6.9 ± 16.10
End of Study-9.3 ± 13.61
Early Withdrawal-6.1 ± 9.51
SecondaryChange From Baseline in Total Swollen Joint Counts (28 Joints)

The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1, for 28 joints and were classified as swollen/not swollen giving a total possible swollen joint count of 0 to 28. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to Week 104)
Reported as:
Mean · swollen joints
Change From Baseline in Total Swollen Joint Counts (28 Joints)
swollen jointsTocilizumab
Baseline4.8 ± 4.67
Week 12-2.5 ± 3.42
Week 24-2.0 ± 3.24
Week 36-2.1 ± 3.61
Week 48-2.4 ± 3.90
Week 56-2.7 ± 3.91
Week 68-2.9 ± 3.90
Week 80-2.5 ± 4.42
Week 92-3.0 ± 5.45
End of Study-2.8 ± 4.12
Early Withdrawal-4.3 ± 5.28
SecondaryPercentage of Participants With Drug-Free Remission

Drug-free remission was defined as having clinical remission (defined as DAS28-ESR score \<2.6) for 2 consecutive assessment visits followed by discontinuation of tocilizumab at the second assessment visit. DAS28-ESR was calculated from swollen joint count and tender joint count using 28 joints count, ESR, (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment on a 0 to 100 mm VAS; higher scores indicating greater affectation due to disease activity). Total DAS28-ESR transformed score range: 0 to approximately 10, higher score=more disease activity.

Time frame:
Baseline up to Week 104 (assessed at Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit [Week 104], at early withdrawal [up to 104 weeks])
Reported as:
Number · percentage of participants
Percentage of Participants With Drug-Free Remission
percentage of participantsTocilizumab
Percentage of Participants With Drug-Free Remission0.0
SecondaryPercentage of Participants With Clinical Remission

Clinical remission was defined as having DAS28-ESR score \<2.6 at any point during the study. DAS28-ESR was calculated from swollen joint count and tender joint count using 28 joints count, ESR, (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment on a 0 to 100 mm VAS; higher scores indicating greater affectation due to disease activity). Total DAS28-ESR transformed score range: 0 to approximately 10, higher score=more disease activity.

Time frame:
Baseline up to Week 104 (assessed at Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit [Week 104], at early withdrawal [up to 104 weeks])
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Remission
percentage of participantsTocilizumab
Percentage of Participants With Clinical Remission81.6
SecondaryTime to Rheumatoid Arthritis (RA) Flare in Participants Who Had Entered Drug-Free Remission

Time to RA flare was defined as the period of drug-free remission (having DAS28-ESR score \<2.6 for 2 consecutive assessment visits followed by discontinuation of tocilizumab at the second assessment visit) until documented RA flare. RA flare was defined as any worsening of the participant's disease activity that, in the opinion of the Investigator, required treatment intensification beyond supportive therapy which could include restarting the study drug.

Time frame:
Baseline up to Week 104 (assessed at Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit [Week 104], at early withdrawal [up to 104 weeks])

No measurements were reported for this outcome.

SecondaryChange From Baseline in Physician's Global Assessment (PGA) of Disease Activity Using Visual Analog Scale (VAS)

The PGA of disease activity was assessed using a 0 to 100 mm horizontal VAS by the physician. The left-hand extreme of the line equaled 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equaled 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicated improvement. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)
Reported as:
Mean · mm
Change From Baseline in Physician's Global Assessment (PGA) of Disease Activity Using Visual Analog Scale (VAS)
mmTocilizumab
Baseline32.1 ± 24.60
Week 12-15.1 ± 21.57
Week 24-16.0 ± 19.05
Week 36-17.3 ± 19.37
Week 48-18.0 ± 20.06
Week 56-19.0 ± 20.60
Week 68-20.6 ± 22.13
Week 80-19.2 ± 19.01
Week 92-21.2 ± 17.50
End of Study-22.2 ± 20.92
Early Withdrawal-2.9 ± 22.71
SecondaryChange From Baseline in PtGA of Disease Activity Using VAS

The PtGA of disease activity was assessed using a 0 to 100 mm horizontal VAS by the participant. The left-hand extreme of the line equaled 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equaled 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). A negative change from baseline indicated improvement. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)
Reported as:
Mean · mm
Change From Baseline in PtGA of Disease Activity Using VAS
mmTocilizumab
Baseline34.9 ± 27.33
Week 12-10.1 ± 21.63
Week 24-6.4 ± 20.57
Week 36-11.4 ± 20.14
Week 48-9.1 ± 21.24
Week 56-8.5 ± 19.14
Week 68-11.0 ± 21.54
Week 80-16.0 ± 24.10
Week 92-12.8 ± 12.40
End of Study-16.4 ± 22.13
Early Withdrawal5.4 ± 34.88
SecondaryChange From Baseline in Participant Assessment of Pain Using VAS

Severity of pain was evaluated by a VAS. Participants marked on a 100 mm horizontal VAS the severity of pain that they had experienced because of their RA, ranging from 0 mm (no pain) to 100 mm (unbearable pain). Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from the study for the reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)
Reported as:
Mean · mm
Change From Baseline in Participant Assessment of Pain Using VAS
mmTocilizumab
Baseline35.0 ± 26.48
Week 12-11.6 ± 20.80
Week 24-8.4 ± 19.74
Week 36-12.7 ± 19.05
Week 48-10.9 ± 19.96
Week 56-9.9 ± 19.71
Week 68-11.7 ± 20.16
Week 80-15.3 ± 22.22
Week 92-10.9 ± 13.59
End of Study-17.2 ± 20.13
Early Withdrawal-0.7 ± 32.62
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

The HAQ-DI was a participant self-reported questionnaire for assessing the extent of a participant's functional ability. It consisted of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question had 4 response options, ranging from 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. The HAQ-DI scale was an average of all the scores from all questions and ranged from 0 to 3, where higher scores represented higher disease activity. Participants who completed the study, or discontinued the study as per sponsor discretion due to marketing authorization approval, were included in End of Study Visit which was Week 104. Participants who withdrew from study for reason other than sponsor discretion due to marketing authorization approval, were included in Early Withdrawal Visit. Participants with "Unspecified" reason of discontinuation were excluded for change from baseline analysis.

Time frame:
Baseline, Weeks 12, 24, 36, 48, 56, 68, 80, 92, at end of study visit (Week 104), at early withdrawal (up to 104 weeks)
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
units on a scaleTocilizumab
Baseline0.871 ± 0.5981
Week 12-0.169 ± 0.3255
Week 24-0.163 ± 0.4301
Week 36-0.208 ± 0.4965
Week 48-0.106 ± 0.5001
Week 56-0.185 ± 0.5024
Week 68-0.076 ± 0.4154
Week 80-0.152 ± 0.4095
Week 92-0.271 ± 0.3100
End of Study-0.239 ± 0.5698
Early Withdrawal0.019 ± 0.2230

Adverse events

Collected over Baseline up to 112 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab—3/38 (7.9%)22/38 (57.9%)
Most frequent serious events
Most frequent serious events
EventTocilizumab
Vestibular neuronitisInfections and infestations1/38
Myocardial ischemiaCardiac disorders1/38
Speech disorderNervous system disorders1/38
VertigoEar and labyrinth disorders1/38
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTocilizumab
Alanine aminotransferase increasedInvestigations11/38
HypercholesterolaemiaMetabolism and nutrition disorders6/38
Upper respiratory tract infectionInfections and infestations5/38
NasopharyngitisInfections and infestations4/38
BronchitisInfections and infestations3/38
Hepatic enzyme increasedInvestigations3/38
ThrombocytopeniaBlood and lymphatic system disorders2/38
DiarrhoeaGastrointestinal disorders2/38
PharyngitisInfections and infestations2/38
Aspartate aminotransferase increasedInvestigations2/38

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were enrolled in the study and received at least 1 tocilizumab dose during the study.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean52.3 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female32
Male6
08

Study locations

4 sites
  • Bytom, 41-902, Poland
  • Elblag, 82-300, Poland
  • Poznan, 60-218, Poland
  • Warszawa, 02-637, Poland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2012
First posted
Aug 15, 2012
Start
Jul 2012
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Results first posted
Feb 8, 2018
Last update
Feb 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01665430
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 15, 2012
Start date
Jul 2012
Primary completion
Feb 2015
Completion
Feb 2015
Results posted
Feb 8, 2018
Last update
Feb 8, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion